Regulation of Th17 Differentiation by Epidermal Fatty Acid-Binding Protein

Bing Li, Joseph M. Reynolds, Robert D. Stout, David A. Bernlohr and Jill Suttlles

*J Immunol* 2009; 182:7625-7633; doi: 10.4049/jimmunol.0804192
http://www.jimmunol.org/content/182/12/7625

References
This article cites 43 articles, 16 of which you can access for free at:
http://www.jimmunol.org/content/182/12/7625.full#ref-list-1

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Regulation of Th17 Differentiation by Epidermal Fatty Acid-Binding Protein

Bing Li,* Joseph M. Reynolds,* Robert D. Stout,* David A. Bernlohr, † and Jill Suttles2*†

Epidermal fatty acid-binding protein, E-FABP, a lipid chaperone, has been shown to regulate the inflammatory function of macrophages and dendritic cells. Herein, we demonstrate that T cell expression of E-FABP promotes Th17 differentiation, while counterregulating development of FoxP3+ regulatory T cells (Tregs). In response to immunization with myelin oligodendrocyte glycoprotein peptide (MOG35–55), E-FABP-deficient mice generated reduced levels of Th17 cells and elevated levels of Tregs, as compared with wild-type mice. Likewise, naive CD4+ T cells isolated from E-FABP-deficient mice showed reduced expression of IL-17 and enhanced expression of FoxP3, in vitro, when subjected to Th17 or Treg polarizing conditions, respectively. It has been demonstrated previously that IL-21, induced by IL-6, stimulates the expression of the nuclear receptors retinoic acid-related orphan receptor (ROR)γt and RORα, which in turn induce expression of IL-17. We found that the impaired Th17 differentiation by E-FABP-deficient CD4+ T cells was associated with lower levels of IL-21 expression in response to IL-6, as well as reduced expression of RORγt and RORα. However, E-FABP-deficient CD4+ T cells expressed significantly higher levels of the nuclear receptor peroxisome proliferator-activating receptor (PPAR)γ than did wild-type CD4+ T cells, and treatment with the PPARγ antagonist GW9662 restored expression of IL-21, RORγt, RORα, and IL-17 by E-FABP-deficient T cells to wild-type levels. The negative influence of E-FABP deficiency on IL-17 expression was attributed to PPARγ-mediated suppression of IL-6-induced STAT3 activity. Thus, taken together, our data indicate that expression of E-FABP by CD4+ T cells contributes to the control of IL-6 stimulation of the IL-21/ROR/IL-17 pathway and to the Th17/Treg counterbalance. The Journal of Immunology, 2009, 182: 7625–7633.

Fatty acid-binding proteins, FABPs, consist of a family of small, highly homologous cytosolic proteins that display distinct patterns of tissue distribution (1). FABPs are capable of binding a variety of hydrophobic compounds, with the specificity and affinity of ligand binding varying among the various family members. Evidence suggests that a general function of FABPs is to shuttle lipid ligands to intracellular compartments or enzyme systems within the cell (1, 2). Studies of FABP-deficient mice have revealed a role of epidermal FABP (E-FABP) and adipose FABP (A-FABP) in the development of obesity, insulin resistance, and atherosclerosis (3). Recent work has revealed a role of these two FABPs in the regulation of macrophage and dendritic cell (DC) inflammatory function. We have shown that A-FABP deficiency in macrophages results in elevated activity of the lipid-ligated nuclear receptor peroxisome proliferator-activating receptor (PPAR)γ. Elevated PPARγ activity, in turn, up-regulates expression of genes involved in cholesterol trafficking while down-regulating expression of genes encoding proinflammatory proteins (4). DCs deficient for A-FABP and/or E-FABP do not effectively promote Th1 differentiation in vitro (5, 6), and FABP-deficient mice immunized with myelin oligodendrocyte glycoprotein (MOG35–55) show protection from development of experimental autoimmune encephalomyelitis (EAE), with reduced levels of IFN-γ and IL-17 in CNS tissue as compared with wild-type mice.

Development of EAE has been shown to involve both Th1 and Th17 T cell subsets, each of which plays distinct roles in disease pathogenesis (7–9). Development and progression of EAE is attenuated by FoxP3+ regulatory T cells (Tregs) (10), and recent studies have shown that Th17 and Treg differentiation are reciprocally regulated (11, 12). Th17 differentiation can be initiated by a combination of TGFβ and IL-6 in mice (13, 14), and it is maintained by IL-23 (15). IL-21, induced by IL-6, acts in an autocrine fashion to promote Th17 cell differentiation (16). IL-21 induces expression of the nuclear receptor superfamily members retinoic acid-related orphan receptor (ROR)γt and RORα (15, 17). Both RORγt and RORα contribute to the induction of T cell expression of IL-17 (17, 18), and double deficiency of these two transcription factors impairs Th17 development and protects mice against development of EAE (17). Interestingly, IL-6, which promotes Th17 differentiation when in combination with TGFβ, inhibits the generation of FoxP3+ Tregs (11), whereas TGFβ-induced FoxP3 has been shown to antagonize RORγt and RORα function (12, 19). Thus, the Th17 and Treg differentiation programs are antagonistic and the polarization toward one or the other functional phenotype can be modulated by the cytokine milieu (12).

In addition to the role of RORγt and RORα in Th17 differentiation, there is evidence that other members of the nuclear
receptor superfamily influence the Th17/Treg balance. For example, the retinoic acids (RAs) all-trans RA (ATRA), a ligand for retinoic acid receptor (RAR) nuclear receptor family members, and 9-cis RA (9-cis-RA), a ligand for both retinoid X receptors (RXRs) and RARs, have been shown to both induce Treg differentiation and inhibit Th17 differentiation (20). Additionally, there is evidence that PPARγ expression by Tregs is essential for their regulatory function (21). Interestingly, E-FABP is capable of binding RAs, and there is overlap in ligand binding specificities between E-FABP and PPAR family members (22–24). These observations led to a number of studies that have linked FABP expression with RA transport, as well as with PPAR activity, in a variety of cell culture systems. For example, there is evidence for E-FABP transport of RA to the nucleus (24), and there are studies suggesting that FABPs may act to sequester PPAR ligands in the cytoplasm, hence inhibiting nuclear entry and PPAR activity (4, 25, 26).

In our previous study of the impact of deficiency of A-FABP and E-FABP on the development of EAE, we focused on the role of macrophages and DCs (6). Although A-FABP expression is primarily restricted to macrophages, DCs, and adipocytes, E-FABP is the most widely expressed of the various FABP family members and is expressed in most leukocyte populations, including CD4+ T cells (5). Given the dramatic differences in IL-17 expression between FABP-deficient mice and wild-type mice at the sites of inflammation in the EAE model (6), we explored the possibility that the presence of E-FABP in T cells may influence IL-17 expression. We provide evidence that E-FABP contributes to the regulation of Th17 differentiation in vitro and during the development of EAE in vivo.

Materials and Methods

Mice

Mice deficient for E-FABP were generated as previously described (27) and backcrossed >10 generations onto a C57BL/6 background. The E-FABP-deficient mice were re-derived, bred, and maintained in the University of Louisville Research Resources Facility. All animal care and experimental procedures used in this study were approved by the University of Louisville Institutional Animal Care and Use Committee.

Induction of EAE

MOG15–55 peptide corresponding to the sequence MEVGWYRSPFS RVVHYLNYRGK was purchased from Bio-Synthese. Mice were injected in the flank with a 100 μl of emulsion containing 150 μg of MOG15–55 in CFA (Sigma-Aldrich) supplemented with 500 ng of Mycobacterium tuberculosis H37Ra (Difco Laboratories). Mice were immunized as described above. Draining lymph nodes were harvested 11 days postimmunization and cultured for 5 days in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, t-glutamine, HEPES, sodium pyruvate, and 2-ME in the presence of MOG15–55 immediately following MOG15–55 injection and again 2 days postimmunization. For adoptive transfer of EAE, C57BL/6 female mice were immunized as described above. Draining lymph nodes were harvested 11 days postimmunization and cultured for 5 days in RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin, t-glutamine, HEPES, sodium pyruvate, and 2-ME in the presence of MOG15–55 (25 μg/ml) and recombinant murine IL-23 (10 ng/ml; R&D Systems) for maintenance of the Th17 phenotype, as previously described (28, 29). Following in vitro culture, the cells were analyzed by flow cytometry, which confirmed the presence of Th17 (CD4+, IL-17+), but not Th1 (CD4+, IFN-γ) cells, as has been reported previously (28). Cells were harvested, washed, and 1.5 × 106 cells were transferred to wild-type and E-FABP-deficient female mice via the tail vein. Mice were given 250 ng of pertussis toxin i.p. on days 0 and 2 posttransfer. The animals were scored daily for clinical symptoms of EAE. Clinical scores were designated numerically according to the following: 0, no detectable EAE symptoms; 1, tail paralysis/loss of tone; 2, normal gait; 3, hind limb paralysis; 4, hind limb and forelimb paralysis; and 5, moribund or dead; 0.5 gradations were assigned for intermediate scores.

Cell isolation and cell culture conditions

Single cells from CNS were isolated using Neural Tissue Dissociation kits (Miltenyi Biotec) per the manufacturer’s instructions. For analysis of Th17/Treg differentiation, naïve CD4+ T cells were purified from spleen of C57BL/6 and E-FABP-deficient female mice by using CD4+ CD62L+ T cell isolation kits (Miltenyi Biotec). Purified T cells were plated at a ratio of 1:5 with irradiated (3000 rad) splenic feeder cells in RPMI 1640 medium supplemented with 5% FBS, 2 mM L-glutamine, 10 mM HEPES, 2.5 μM 2-ME, 5 μg/ml insulin-transferring selenium, 10 μg/ml gentamicin, 100 μg/ml penicillin, and 100 μg/ml streptomycin (Sigma-Aldrich). Cells were stimulated with 2.5 μg/ml anti-CD3 (clone 145-141). For Th17-promoting conditions, cultures were supplemented with 5 ng/ml recombinant human TGFβ1 (R&D Systems), 20 ng/ml recombinant murine IL-6 (R&D Systems), and E-FABP-deficient female mice via the tail vein. Mice were given 250 ng of pertussis toxin i.p. on days 0 and 2 posttransfer. The animals were scored daily for clinical symptoms of EAE. Clinical scores were designated numerically according to the following: 0, no detectable EAE symptoms; 1, tail paralysis/loss of tone; 2, normal gait; 3, hind limb paralysis; 4, hind limb and forelimb paralysis; and 5, moribund or dead; 0.5 gradations were assigned for intermediate scores.

Flow cytometric analysis

For analysis of cytokine synthesis via flow cytometry, cells were restimulated for 5–6 h with 50 ng/ml PMA (Sigma-Aldrich) and 750 ng/ml ionomycin (Calbiochem). After 1 h, GolgiStop (BD Biosciences) was added. Cells were stimulated with anti-CD3 and anti-CD28 antibodies. Cells were washed and stained for 15–30 min at 4°C with allophycocyanin-conjugated anti-CD4 mAb (clone RM45; BD Biosciences) in PBS supplemented with 1% BSA and 0.2% sodium azide. T cells were fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences) and stained intracellularly with PE-conjugated anti-IL-17 (anti-IL-17A, clone TC11-18H10; BD Biosciences), FITC-labeled anti-IFN-γ (clone XMG1.2; BD Biosciences), or PE-Foxp3cri (clone FJK-16s; eBioscience). Samples were acquired on a FACSCalibur flow cytometer and data analysis was conducted using FlowJo software (Tree Star).

Quantitative real-time RT-PCR analysis

mRNA was isolated from cultured cells and converted to cDNA using MACS One-step cDNA columns (Miltenyi Biotec). Real-time RT-PCR was performed using a DNA-Opticon 3 monitor (Bio-Rad) using SYBR Green (Qiagen). RORγt, RORα, IL-17, IL-21, RARα, RARγ, PPARγ, PPARα, PPARβ/δ, PPARγ, and β-actin expression was analyzed by QuantiTect primer assays (Qiagen). Results were normalized to β-actin. Relative expression of RNA transcripts was quantified using the relative expression software tool, REST (30).

Western blot analysis

Naive or activated CD4+ T cells were lysed in buffer containing 25 mM Tris-HCl, 1% deoxycholate, 0.35 M NaCl, phosphatase inhibitor solution (Cayman Chemical), and 1% Triton X-100 (Fisher Scientific). Protein quantity was assayed by bicinchoninic acid (Pierce), and 20 μg of protein was loaded per well on a 15% Tris-HCl gel (Bio-Rad). The contents of the gel were transferred in a Trans-Blot semi-dry transfer cell (Bio-Rad) onto nitrocellulose membranes (Amersham Biosciences). The membranes were incubated with different Abs. Ab-bound proteins were detected using an ECL Western blotting analysis system (Amersham Biosciences), and the membranes were exposed to Kodak Biomax XL x-ray film.

PPARγ activity and STAT3 DNA binding assays

Nuclear proteins isolated from 5 × 106 naïve CD4+ T cells or differentiated Th17 cells from wild-type (WT) and E-FABP-deficient mice were extracted using nuclear extraction kits purchased from Cayman Chemical. PPAR activity was measured using Cayman Chemical’s transcription factor assay kits. Briefly, 10 μg of the extracted nuclear proteins was added to wells containing immobilized specific dsDNA sequences corresponding to the peroxisome proliferator response element. Bound PPARγ was detected by addition of specific Ab to PPARγ. Relative PPAR activity was measured by comparison with an unstimulated WT control. Activation of STAT3 in nuclear lysates was measured using 10 μg of nuclear extract from the immunized sample and TransAM STAT3 ELISA (Active Motif). Activated STAT3 in nuclear extracts bound to immobilized STAT3 consensus oligonucleotide was detected using an Ab directed against STAT3 followed by a HRP-conjugated secondary Ab and colorimetric analysis at 450 nm.
Th17 cells were transferred to poly-n-lysine-coated microslides (Santa Cruz Biotechnology), and 13-HODE-biotin (Cayman Chemical) was added at 5 μM for 3 h. Cells were washed with PBS then fixed for 30 min at ambient temperature with 4% paraformaldehyde. The cells were permeabilized for 2 min with 0.1% Triton X-100 (Fisher) in PBS and blocked for 30 min with BSA (Fisher). The cells were labeled with streptavidin Alexa Fluor 568 for detection of biotinylated 13-HODE, as well as FITC-conjugated anti-PPARγ Ab (Santa Cruz Biotechnology). For E-FABP staining, the cells were treated with a primary rabbit anti-E-FABP (31) in PBS, followed by Alexa Fluor 488-conjugated chicken anti-rabbit IgG (Invitrogen). The cells were incubated with 300 nM 4',6-diamidino-2-phenylindole (DAPI; Invitrogen) for 5 min. Coverslips were mounted onto glass microscopy slides (Fisher) with Dako fluorescent mounting medium. Confocal microscopy was performed using an Olympus 3 laser scanning microscope at ×120 magnification.

Statistical analysis

The Student t test was performed for comparisons of disease clinical score, levels of cytokine production, and ratios of IL-17 as cells expressing both IL-17 and IFN-γ.

Results

E-FABP-deficient mice subjected to EAE have reduced T cell expression of IL-17 concomitant with enhanced expression of FoxP3

In previous work, we demonstrated that E-FABP-deficient macrophages and DCs are defective in expression of inflammatory cytokines and are inefficient in the promotion of proinflammatory T cell responses during Ag presentation (6). In mice deficient for both A-FABP and E-FABP, we saw greatly reduced IL-17 expression in CNS tissue, as compared with WT mice following induction of EAE (6). Since E-FABP is expressed in T cells (5), we tested the possibility that E-FABP deficiency may affect T cell IL-17 expression in a manner that contributes to the disease-protective effect of FABP deficiency. To address this question, we examined T cells isolated from MOG35–55-immunized E-FABP-deficient and WT mice. As found previously (6), E-FABP-deficient mice showed reduced clinical symptoms of EAE as compared with WT mice (Fig. 1A). Cells isolated from lymph node, spleen, and CNS were analyzed by flow cytometry for expression of IL-17 and IFN-γ. As shown in Fig. 1B, E-FABP-deficient mice produced greatly reduced numbers of IL-17+CD4+ T cells, as well as cells expressing both IL-17 and IFN-γ, which have been identified previously in the EAE model (32) and in human memory T cell populations (33). In each of these tissues, the reduction in IL-17+ T cells associated with E-FABP deficiency ranged from ~60 to 70%. The percentages of IFN-γ+CD4+ T cells were not significantly different, and overall percentages of CD4+ T cells did not differ, as previously reported (6).

Recent work has shown that IL-17 and FoxP3 are counterregulated via transcription factor antagonism (12). Therefore, we considered it likely that the decreased IL-17 expression by T cells isolated from E-FABP-deficient mice may be accompanied by enhanced expression of FoxP3. Expression of FoxP3 in T cells isolated from lymph node, spleen and CNS of MOG35–55-immunized mice (as above) was evaluated via flow cytometry. Indeed, FoxP3 expression was found to be higher in E-FABP-deficient mice than in their WT counterparts (Fig. 1C). The results of three separate experiments in which expression of IL-17 and FoxP3 was evaluated are shown as histograms in Fig. 1D. The reciprocal expression of FoxP3 vs IL-17 was clearly apparent, particularly in the CNS compartment. These results suggest that E-FABP deficiency favors FoxP3 expression/Treg differentiation over IL-17 expression, thus resulting in a T cell functional profile that is protective.
from development of disease in the EAE model. Therefore, we speculated that the protection from disease displayed by E-FABP-deficient mice may be overridden by transfer of WT Th17 T cells. To test this possibility, WT MOG35–55-specific Th17 cells, expanded in vitro via Ag stimulation in the presence of IL-23 (28, 29) were transferred into naïve WT and E-FABP-deficient recipients. As shown in Fig. 1E, naïve E-FABP-deficient mice developed disease with identical kinetics and achieving similar clinical scores, as did naïve WT mice upon transfer of WT MOG35–55-specific Th17 cells.

Cytokine-driven Th17 differentiation in vitro is impaired by E-FABP deficiency

In the experiments shown in Fig. 1, a defect in Th17 differentiation during development of disease in vivo was revealed. To further address the mechanisms underlying this defect, we evaluated the influence of E-FABP deficiency on Th17 differentiation in vitro. CD4+ T cells were purified from spleens of WT and E-FABP-deficient mice and expression of E-FABP in WT CD4+ T cells was confirmed by Western blot analysis and confocal microscopy (Fig. 2). Confocal microscopy indicated a cytoplasmic localization of E-FABP, as we have observed previously in macrophages and DCs (our unpublished data). Purified CD4+CD62L+ naïve T cells isolated from spleens of WT and E-FABP-deficient mice were cultured under conditions shown to promote Th17 differentiation, that is, with Ag receptor ligation in the presence of TGFβ and IL-6 (14). Following a 3-day culture period, IL-17- and IFN-γ-expressing cells were identified by intracellular staining and flow cytometric analysis. Activation of T cells with anti-CD3 alone or with IL-6 resulted in induction of modest populations of IFN-γ-producing cells by both WT and E-FABP-deficient T cells. As anticipated, addition of both IL-6 and TGFβ induced a significant population of Th17 cells (∼37%) in the cultures of WT T cells. However, cultures of E-FABP-deficient T cells under these same conditions resulted in ∼10% Th17 cells (Fig. 3A). Consistent with this observation, there was also a greatly reduced level of IL-17 in the culture supernatants of E-FABP-deficient CD4+ T cells subjected to Th17 polarizing conditions as compared with WT T cells, whereas there was no significant difference in IFN-γ production (Fig. 3B).

These data suggested that the levels of E-FABP expression in CD4+ T cells may reflect their polarized state, that is, that polarization toward a Treg phenotype may be associated with a down-regulation of E-FABP expression. To test this possibility, naïve WT CD4+ T cells were cultured under either Th17- or Treg-promoting conditions for 3 days and analyzed for expression of IL-17, Foxp3, and E-FABP by real-time RT-PCR (Fig. 3C). Expression of E-FABP was significantly reduced in T cells cultured under Treg-promoting conditions, a finding that supports a functional relationship between E-FABP expression and Th17 differentiation. For further confirmation of the role of E-FABP, we cultured naïve CD4+ T cells under Th17-polarizing conditions in the presence or absence of the FABP inhibitor UMN2421. UMN2421 was titrated at a range of 1–30 μM (not shown), with a concentration of 10 μM found to be optimal and subsequently used in the experiments shown. Addition of UMN2421 reduced IL-17 expression by WT CD4+ T cells to very near the levels of E-FABP-deficient T cells (a 54% reduction), whereas the inhibitor had no impact on the percentage of IL-17+ cells in the E-FABP-deficient cultures (Fig. 3D). DMSO alone was used as a carrier control and had no effect on IL-17 expression by either group (not shown).

The reduced IL-17 production by E-FABP-deficient T cells in response to TGFβ plus IL-6, as well as the ability of an E-FABP inhibitor to reduce IL-17 expression, indicated that E-FABP promotes the outcome(s) of TGFβ plus IL-6 signaling that lead to IL-17 expression. These outcomes include induction of the retinoic acid receptor-related orphan receptors, RORγt and RORα, which have been shown to drive IL-17 expression (17). We cultured naïve CD4+ T cells isolated from E-FABP-deficient and WT mice as in the experiments presented in Fig. 3A–C and evaluated the expression of RORγt and RORα. Expression of RORγt was very effectively induced by the combination of TGFβ and IL-6 in WT T cells, but only very modestly in T cells from E-FABP-deficient cells (Fig. 3E, left panel). RORα expression was induced in WT cells via TGFβ and IL-6 alone, and more so by the combination of cytokines. However, overall, the expression of RORα was much less than RORγt. Expression of RORα by E-FABP-deficient T cells was only detectable when the cells were cultured with both TGFβ and IL-6 (Fig. 3E, right panel).

E-FABP deficiency promotes RA-induced FoxP3 expression

Since we had observed an enhancement of Tregs in vivo in E-FABP-deficient mice undergoing EAE, we performed in vitro experiments that represented the counterpoint to those presented in Fig. 3, in that naïve CD4+ T cells were driven in vitro toward a Treg phenotype. RAs have been shown to drive Foxp3 expression in response to TGFβ and to counter Th17 culture conditions to favor Foxp3 expression (20). Although ATRA, through RARα, has been shown to influence Treg differentiation indirectly via its influence on an accompanying T cell population (34), we have found that 9-cis-RA acts directly on cultures of purified naïve CD4+ T cells. Naïve CD4+ cells isolated from WT or E-FABP-deficient mice were cultured under Th17 conditions in the presence or absence of 9-cis-RA. Following 3 days in culture, Foxp3 expression was evaluated via intracellular labeling and flow cytometric analysis. As shown in Fig. 4A, treatment with 9-cis-RA resulted in the induction of ∼15% of Foxp3+ T cells in the WT cultures, whereas the same treatment resulted in ∼27% of Foxp3+ T cells in the E-FABP-deficient cultures. These data show a similar trend as was seen in our in vivo experiments (Fig. 1C) and indicate that absence of E-FABP promotes Treg differentiation. Given the dramatic differences in the expression of the nuclear receptors
RORγt and RORα in E-FABP-deficient vs WT cells, we considered the possibility that differences may also exist between the two genotypes in expression of RAR and RXRα, both of which can bind 9-cis-RA. As shown in Fig. 4B, no differences in expression of these nuclear receptors between WT and E-FABP-deficient T cells were observed.
E-FABP-deficient CD4^+ T cells display enhanced PPARγ expression and activity

The data shown in Fig. 4 suggest that E-FABP deficiency enhances FoxP3 expression independent of RAR or RXR expression, and therefore this effect likely occurs via an enhancement of RA availability (i.e., trafficking to the nucleus) or function. For example, 9-cis-RA binding to RXR could provide support for the activity of other nuclear receptors, such as PPARs, through the formation of PPAR/RXR heterodimers. In our previous studies of FABP function in macrophages, we noted an increase in PPARγ activity in FABP-deficient macrophages (4). Thus, we considered PPARs as candidates for the altered regulation of Th17/FoxP3 expression in E-FABP-deficient T cells. To address this possibility, we first analyzed the expression of PPARα, PPARβ/δ, and PPARγ in WT and E-FABP-deficient CD4^+ T cells and found that although equivalent levels of PPARα and PPARβ/δ were expressed by T cells of both genotypes, PPARγ expression was ~10-fold higher in E-FABP-deficient CD4^+ T cells (Fig. 5A). As expected, the higher level of PPARγ in E-FABP-deficient T cells was accompanied by a significantly higher level of PPARγ activity (Fig. 5B). These results implicated PPARγ as a potential mediator of the functional phenotype associated with FABP deficiency in CD4^+ T cells. To address this directly, WT and E-FABP-deficient naive CD4^+ T cells were cultured in Th17-driving conditions in the presence or absence of the PPARγ antagonist GW9662 (5 μM). T cells were recovered and restimulated with PMA plus ionomycin for 5 h and analyzed for IL-17 and IFN-γ expression by intracellular labeling and flow cytometric analysis. In vitro cultured T cells from WT and E-FABP-deficient mice were stimulated for 3 days. PPARγ activity in nuclear lysates was measured by relative comparison with an unstimulated WT control (*, p < 0.05). The defective Th17 production in E-FABP-deficient T cells was successfully restored to near WT levels by inhibition of PPARγ activity with GW9662 treatment, whereas WT T cells were unaffected (Fig. 5C). The role of PPARγ was also assessed by confocal microscopy in which the localization of a PPARγ/E-FABP ligand, 13-HODE, and its interaction with nuclear PPARγ was examined. The enhanced expression of PPARγ (labeled in green) in E-FABP-deficient CD4^+ T cells as compared with WT CD4^+ T cells was apparent (Fig. 5D). Localization of 13-HODE (labeled in red) was largely cytoplasmic in the WT cells, where it is capable of binding to cytoplasmic E-FABP. However, in the absence of E-FABP, 13-HODE freely enters the nucleus. Merging these two labels (Fig. 5D, bottom panel) reveals an enhanced interaction of 13-HODE with nuclear PPARγ in the E-FABP-deficient CD4^+ T cells as compared with WT CD4^+ T cells, in which 13-HODE remains cytoplasmic. Thus, the combination of E-FABP deficiency and elevated PPARγ expression promotes PPARγ ligand nuclear entry and receptor binding.
**FIGURE 6.** The reduced Th17 differentiation exhibited by E-FABP-deficient T cells is mediated by PPARγ. 

A, WT and E-FABP-deficient naive T cells were stimulated with anti-CD3 and anti-CD28 in the presence of combinations of cytokines with or without GW9662 (GW), as indicated. Data shown are representative of three similar experiments (*, p < 0.05; **, p < 0.01). B, Expression of RORγt (left panel) and RORα (right panel) mRNA by naive T cells, cultured as under Th17 conditions with or without GW9662, was analyzed by real-time RT PCR (***, p < 0.01). C, Left panel, Naive CD4+ T cells from WT and E-FABP-deficient mice were purified and stimulated with IL-6 at the indicated time points on plate-bound anti-CD3 and soluble anti-CD28. Cell lysates were analyzed by Western blot using Abs specific for the phosphorylated form of STAT3, or total STAT3, as indicated. The histogram represents ratio of phosphorylated STAT3 to total STAT3 band density. Right panel, CD4+ T cells from WT and E-FABP-deficient mice were treated without or with 13-HODE with or without GW9662 for 3 h followed by a 20-min stimulation with IL-6. STAT3 DNA binding was assayed as described in Materials and Methods. The data are presented as means ± SD of triplicate samples (***, p < 0.01).

PPARγ inhibits the IL-21/ROR/IL-17 axis via inhibition of IL-6-mediated STAT3 activity in E-FABP-deficient CD4+ T cells

Expression of IL-17 by T cells subjected to Th17-polarizing conditions entails IL-6 induction of IL-21, which, in turn, induces expression of RORγt and RORα (15) (17). The activities of both IL-6 and IL-21 are STAT3-dependent (15). PPARγ has been shown to down-regulate the expression of proinflammatory cytokines by antagonizing the function of transcription factors such as NF-κB, AP-1, and STATs (35). PPARγ interference with STAT3 activity has been described in a variety of systems and has been identified as a mechanism of PPARγ inhibition of IL-6-mediated cell signaling (36). Thus, we speculated that the reduced RORγt, RORα, and IL-17 expression displayed by E-FABP-deficient CD4+ T cells is mediated by PPARγ, possibly via inhibition of STAT3 activity. To test this hypothesis, naive CD4+ T cells isolated from WT and E-FABP-deficient mice were stimulated with anti-CD3 and anti-CD28 in the presence of Th17-driving cytokines with or without the addition of the PPARγ antagonist GW9662. We found that production of IL-21 by E-FABP-deficient CD4+ T cells, induced by IL-6, was significantly reduced as compared with WT CD4+ T cells, and that this deficiency was restored completely by addition of GW9662 (Fig. 6A, left panel). Likewise, GW9662 restored the IL-17 production by E-FABP-deficient CD4+ T cells to WT levels (Fig. 6A, right panel). We also evaluated the effect of PPARγ antagonism on RORγt and RORα expression induced under Th17-polarizing conditions, with similar results. Both in the case of RORγt (Fig. 6B, left panel) and RORα (Fig. 6B, right panel), addition of GW9662 brought the level of expression of these nuclear receptors by E-FABP-deficient CD4+ T cells to near the levels expressed by WT CD4+ T cells. Interestingly, GW9662 reduced expression of RORα by WT CD4+ T cells, although this effect was not statistically significant.

These data indicated that PPARγ was responsible for the reduced IL-21, RORγt, RORα, and IL-17 expression exhibited by E-FABP-deficient CD4+ T cells. Given the known influence of PPARγ on STAT3 signaling, we evaluated STAT3 activation following IL-6 stimulation in E-FABP-deficient and WT CD4+ T cells. We found by Western blot analysis that IL-6-induced STAT3 phosphorylation in E-FABP-deficient and WT CD4+ T cells was indistinguishable (Fig. 6C, left panel), suggesting that any impact of PPARγ on STAT3 signaling occurred downstream of STAT3 phosphorylation. In other systems, PPARγ has been shown to disrupt STAT3 DNA binding (36). Therefore, we evaluated IL-6-induced STAT3 DNA binding activity in E-FABP-deficient and WT CD4+ T cells in the presence and absence of GW9662. As shown in Fig. 6C, right panel, E-FABP-deficient T cells displayed reduced STAT3 DNA binding in response IL-6 stimulation. Although this difference did not quite achieve statistical significance.
Importantly, addition of the PPARγ agonist 13-HODE further reduced STAT3 DNA binding in E-FABP-deficient CD4<sup>+</sup> T cells to levels to <50% that of WT, whereas addition of 13-HODE had no impact on STAT3 DNA binding in WT CD4<sup>+</sup> T cells. Addition of GW9662 to IL-6-stimulated CD4<sup>+</sup> T cells (in the absence of 13-HODE) restored the levels of STAT3 DNA binding in E-FABP-deficient CD4<sup>+</sup> T cells to the levels displayed by WT CD4<sup>+</sup> T cells. These data demonstrate that, although STAT3 phosphorylation and nuclear translocation occur in response to IL-6 in E-FABP-deficient T cells, STAT3 DNA binding is impaired and PPARγ is indicated as a mediator of this impairment.

Discussion

Recent work has revealed a role of the FABPs, A-FABP and E-FABP, in potentiating inflammatory responses (4–6). We demonstrated previously that mice deficient for A-FABP, E-FABP, or both (A,E-FABP-deficient) have reduced macrophage and DC inflammatory function, which results in impaired Th1 generation and protection from development of EAE (6). In this prior study, we found that purified T cells derived from A,E-FABP-deficient mice had equivalent proliferative responses to anti-CD3 stimulation in vitro, as well as equivalent IFN-γ production. This indicated that there were no intrinsic defects in the T cells themselves in terms of Th1 generation, and that the poor Th1 generation in vivo and during Ag recall responses in vitro was attributed to the faulty APC activity associated with FABP deficiency. However, we also observed greatly reduced levels of IL-17 present in the CNS of A,E-FABP-deficient mice as compared with WT mice during the course of disease. In the present study, we focused exclusively on E-FABP-deficient mice to investigate the possibility that E-FABP, expressed in T cells, may influence Th17 differentiation and in this process we have made the novel discovery that, indeed, E-FABP contributes to the Th17/Treg differentiation program.

In the examination of CD4<sup>+</sup> T cells in tissues of mice undergoing EAE, we found reduced levels of CD4<sup>+</sup> T cells expressing IL-17 in the E-FABP-deficient mice, which included reduced levels of the CD4<sup>+</sup> T cell population that expressed both IL-17 and IFN-γ (Fig. 1B), which has been characterized recently as a significant population arising during active EAE (32). Given the reports of reciprocal regulation of IL-17 and FoxP3 expression (12), we also examined expression of FoxP3 by CD4<sup>+</sup> T cells from tissues of mice undergoing EAE and confirmed that the reduced IL-17 production by T cells from E-FABP-deficient mice is accompanied by enhanced FoxP3 expression (Fig. 1C). These results indicate that absence of E-FABP in CD4<sup>+</sup> T cells shifts the program of regulation of IL-17 and FoxP3 gene expression, favoring the Treg phenotype, a phenomenon that was corroborated by experiments in which Th17 and Treg phenotypes were driven in vitro (Figs. 3 and 4). The ability of an FABP inhibitor to mimic the E-FABP-deficient state (Fig. 3D) promotes the concept that functional E-FABP, that is, E-FABP capable of lipid ligand binding, influences this gene regulation program. Also of importance is the finding that levels of E-FABP expression in WT CD4<sup>+</sup> T cells diminish with differentiation to the Treg phenotype (Fig. 3C). If the presence of E-FABP promotes IL-17 expression, as is indicated by the data, then one would expect that signals that promote Treg differentiation would reduce E-FABP expression. Currently, studies of the regulation of E-FABP expression are very limited. The data presented herein suggest that mediators that promote antiinflammatory responses and Treg differentiation are likely to suppress E-FABP expression.

Interestingly, accompanying the reduced propensity for Th17 differentiation by E-FABP-deficient CD4<sup>+</sup> T cells was the enhanced propensity for Treg differentiation induced by addition of 9-cis-RA (Fig. 4A). This difference was not associated with differences in expression of the nuclear receptors capable of binding 9-cis-RA, that is, RAR and RXR family members (Fig. 4B), suggesting that E-FABP affects the interaction of 9-cis-RA with its cognate receptors, or the ability of ligand-bound receptors to interact with their heterodimeric partners or gene targets. This phenomenon was reminiscent of our studies of the relationship between FABP expression and PPARγ function in macrophages (4). Our data suggested a scenario by which FABPs restrict PPARγ ligand accessibility to PPARγ via binding and maintaining them in the cytoplasmic compartment. Given that E-FABP has the capacity to bind both retinoids as well as PPAR ligands, we considered the possibility that a similar scenario may exist in CD4<sup>+</sup> T cells. Both 9-cis-RA and PPARγ ligands have been shown to be protective against EAE, and the combination of both provides additive protection from disease (37, 38). The amelioration of EAE by PPARγ agonists and by 9-cis-RA has been largely attributed to their ability to inhibit production of Th1-promoting cytokines by APCs, and to reduce inflammatory function of glial cells (34, 37, 39). However, recent studies have also provided evidence for direct effects of retinoids, including 9-cis-RA, on T cell cytokine production (40, 41) and a direct influence of PPARγ expression by Tregs on their functional capacity (21). Interestingly, in our assessment of a potential influence of PPARs in E-FABP-deficient CD4<sup>+</sup> T cells, we saw enhanced expression of PPARγ, accompanied by enhanced activity (Fig. 5A), whereas the enhanced effect of 9-cis-RA was independent of RAR or RXR receptor expression (Fig. 4B).

The enhanced PPARγ expression/activity was a likely candidate as a mediator of the reduced IL-17 expression by E-FABP-deficient CD4<sup>+</sup> T cells based on the previous publications demonstrating an inhibitory effect of PPARγ on STAT3 activity (36, 42). Indeed, we found that antagonism of PPARγ activity effectively reversed the reduced IL-21, RORγt, RORα, and IL-17 expression exhibited by E-FABP-deficient T cells (Fig. 6, A and B), which confirmed the role of PPARγ in suppression of Th17 differentiation. We also present evidence that this effect of PPARγ was due to inhibition of STAT3 DNA binding, a phenomenon that has been previously reported (36). Given that RAR and RXR expression are equivalent between E-FABP-deficient and WT CD4<sup>+</sup> T cells, we think that the enhanced effect of 9-cis-RA on FoxP3 expression is likely due to the provision of RXR heterodimeric partnering to PPARγ, which is enhanced in E-FABP-deficient cells. This concept is supported by preliminary data demonstrating that GW9662 reduces FoxP3 expression in E-FABP-deficient CD4<sup>+</sup> T cells (not shown).

Still under investigation is the mechanism by which PPARγ expression is elevated in E-FABP-deficient T cells. PPARγ expression in other cell types (e.g., adipocytes) has shown to be influenced by cholesterol levels and dietary fat intake (43). Thus, it is likely that dysregulated lipid trafficking in the absence of E-FABP may impact lipid availability in a manner that acts to boost PPARγ expression. Additionally, the studies performed herein used exclusively female mice due to their enhanced susceptibility to development of disease in the EAE model. Preliminary data suggest that the reduced IL-17 associated with E-FABP deficiency is less pronounced in male mice, indicative of a gender influence of E-FABP. Previous studies have found gender differences in PPAR family member expression (44), which we will explore as a possible contributor to this observed phenomenon. In summary, we have made the novel observation that expression of the lipid chaperone E-FABP in CD4<sup>+</sup> T cells promotes IL-17 expression and that absent or reduced E-FABP expression is associated with enhanced expression of FoxP3. E-FABP expression in CD4<sup>+</sup> T cells is negatively correlated with expression of PPARγ,
which is capable of suppressing IL-6 activation of the STAT3/IL- \( 22 \)/ROR-\( \gamma \)-IL-17 pathway. The finding that the E-FABP expression modulates the Th17/Treg balance suggests that mediators and mechanisms that regulate E-FABP expression or function may serve as targets for manipulation of this balance, thereby regulating outcomes of autoimmune and inflammatory disease.

Acknowledgments

The authors acknowledge the excellent technical assistance of Lizhong Zhang and Meena Vanchinathan.

Disclosures

The authors have no financial conflicts of interest.

References


